Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.68 |
| ▸ | CA2 | P00918 | 4/20 | 0.68 |
| ▸ | CA7 | P43166 | 4/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.68 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl(Benzylsulfamoyl)Amine SCHEMBL2298224 | 0.82 | CA12 (1.00) | CA12CA2CA7CA14CA1 | |
| SCHEMBL1134868 | 0.79 | CA2 (0.76) | CA12CA2CA7CA14CA1 | |
| SCHEMBL171653 | 0.77 | CA2 (0.61) | CA12CA2CA7CA14CA1 | |
| Trifluoroacetic Acid SCHEMBL7348284 | 0.76 | CA12 (0.52) | CA12CA2CA7CA14CA1 | |
| SCHEMBL27814807 | 0.76 | HIF1A (0.43) | CA12CA2CA7CA14HTT | |
| SCHEMBL22462469 | 0.76 | SIGMAR1 (0.53) | CA12CA2CA7CA14CA1 | |
| SCHEMBL1256517 | 0.75 | OPRM1 (0.45) | CA12CA2CA7CA14CA1 | |
| SCHEMBL11408585 | 0.75 | CA2 (0.76) | CA12CA2CA7CA14CA1 | |
| SCHEMBL24767434 | 0.74 | CA2 (0.57) | CA12CA2CA7CA14CA1 | |
| SCHEMBL19785139 | 0.74 | CA12 (0.74) | CA12CA2CA7CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263597-B2 | Indazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-8008327-B2 | Indazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2285783-A1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2011-02-23 | — | — | EP | disclosed |
| US-20110034512-A1 | Indazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2009134666-A1 | INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294808-A1 | Indazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCRL2 | CA12 4158/4885CA2 2798/4885CA7 2216/4885 |
| US-20110034512-A1 | Indazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCRL2 | CA12 4158/4885CA2 2798/4885CA7 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.